Senti Biosciences Holdings, Inc. - 8-K Filing
Senti Biosciences amends securities purchase agreement to allow third tranche for NSG; faces Nasdaq delisting risks due to bid price and equity deficiencies (Items: 1.01 Entry Into a Material Definitive Agreement, 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, 9.01 Financial Statements and Exhibits)
Tickers: $SNTI